On Wednesday, Silence Therapeutics (NASDAQ:SLN) shares received a continued endorsement from H.C. Wainwright, with the firm reiterating its Buy rating and a $75.00 price target on the stock.
This affirmation comes after Silence Therapeutics presented end-of-treatment data from its Phase 2 trial, ALPACAR-360, during the American Heart Association (AHA) Scientific Sessions on November 18, 2024. The data, which was also simultaneously published in the Journal of the American Medical (TASE:PMCN) Association (JAMA), detailed the effects of zerlasiran on patients.
Zerlasiran, a short interfering RNA (siRNA) targeting the LPA gene, showed promising results in the trial. The treatment, administered in doses of 300 mg every 16 weeks, 300 mg every 24 weeks, or 450 mg every 24 weeks, led to more than 80% mean time-averaged placebo-adjusted reductions from baseline in Lp(a) concentrations over a 36-week period. Moreover, mean maximum Lp(a) reductions exceeded 90%, showcasing the drug's potential efficacy.
Despite the encouraging trial results, Silence Therapeutics' shares experienced a significant drop, falling more than 40% since November 15, 2024. This decline included a more than 30% drop within a single day on Tuesday. The market's reaction contrasts with the biotech index XBI, which saw an approximate 0.5% increase during the same period.
H.C. Wainwright's analysis suggests that the market reaction may be an overreaction. The firm believes that the data supports the advancement of zerlasiran to Phase 3 trials. Furthermore, they anticipate that Silence Therapeutics will be able to establish a strong collaboration to progress the drug's development in 2025.
The reiteration of the Buy rating and price target by H.C. Wainwright underscores their confidence in Silence Therapeutics' prospects, especially in light of the recent trial data and subsequent market response. Silence Therapeutics continues its work in the development of gene-silencing therapies with the potential to address various diseases.
In other recent news, Silence Therapeutics has been making significant strides in the biotechnology sector. The company reported positive trial results for its lead siRNA candidate, Zerlasiran, which has shown significant efficacy in lowering Lp(a), a causal risk factor for cardiovascular disease, by more than 90%.
The company's second candidate for treating Polycythemia Vera, a hematologic disease, has also demonstrated promising Phase 1 data. These developments have prompted firms such as Jefferies, H.C. Wainwright, and BMO Capital to maintain positive ratings on Silence Therapeutics' stock.
Despite concerns about the potential impact of Muvalaplin, a competitive oral medication, on Zerlasiran's market prospects, BMO Capital believes the market's reaction is excessive and sees no safety issues or competitive threats from the new data. Silence Therapeutics also received a $2.0 million milestone payment from Hansoh Pharmaceutical (TADAWUL:2070) Group Company Limited, marking progress in their partnership to develop short interfering RNAs.
Lastly, the company announced the retirement of board member Alistair Gray, but maintains a robust financial position with over $200 million expected to last into 2026. These are recent developments that investors and stakeholders in the biotechnology sector are closely watching as Silence Therapeutics navigates the competitive landscape and seeks to establish strategic partnerships.
InvestingPro Insights
Recent InvestingPro data provides additional context to Silence Therapeutics' (NASDAQ:SLN) current situation. The company's market capitalization stands at $326.18 million, reflecting the recent stock price decline. This decline is evident in the stock's performance metrics, with a 54.27% drop in the past week and a 61.26% fall over the last month, aligning with the article's mention of a significant share price drop.
Two relevant InvestingPro Tips highlight that the stock's RSI suggests it's in oversold territory, and it has taken a big hit over the last week. These tips corroborate the article's discussion of the recent sharp decline in share price, despite positive trial results.
It's worth noting that analysts anticipate a sales decline in the current year, with revenue for the last twelve months as of Q3 2024 at $21.72 million, showing a 42.07% decrease. This financial context adds depth to the market's reaction discussed in the article.
For investors seeking a more comprehensive analysis, InvestingPro offers 9 additional tips for Silence Therapeutics, providing a broader perspective on the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.